---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-009474"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2025-01-28T23:59:59+00:00"
generated_at: "2026-05-27T08:27:09.281680+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics reports positive Phase 1 topline results for T1D therapy SAB-142; plans Phase 2b in 2025

## Summary
- Phase 1 trial of SAB-142 met primary safety and PD objectives; generally well-tolerated, no serum sickness or anti-drug antibodies at target dose.
- SAB-142 showed sustained immunomodulation with MoA analogous to rabbit ATG, correlative to C-peptide preservation.
- Company plans to advance SAB-142 into Phase 2b trial in 2025 for adult and pediatric patients with new-onset T1D.
- Results presented at R&D webinar on Jan 28, 2025; KOL Michael Haller, MD from Univ of Florida participated.

## SEC filing metadata
- accession: 0000950170-25-009474
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2025-01-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000095017025009474/0000950170-25-009474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000095017025009474/sabs-20250128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-009474
- JSON: https://secwatch.observer/filing/0000950170-25-009474.json
- Plain text: https://secwatch.observer/filing/0000950170-25-009474.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.